In last trading session, Bicara Therapeutics Inc (NASDAQ:BCAX) saw 0.35 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $13.00 trading at -$0.82 or -5.93% at ring of the bell on the day assigns it a market valuation of $707.40M. That closing price of BCAX’s stock is at a discount of -116.08% from its 52-week high price of $28.09 and is indicating a premium of 14.62% from its 52-week low price of $11.10.

Bicara Therapeutics Inc (NASDAQ:BCAX) trade information

Upright in the red during last session for losing -5.93%, in the last five days BCAX remained trading in the red while hitting it’s week-highest on Tuesday, 02/18/25 when the stock touched $13.00 price level, adding 9.85% to its value on the day. Bicara Therapeutics Inc’s shares saw a change of -25.37% in year-to-date performance and have moved -0.91% in past 5-day. Bicara Therapeutics Inc (NASDAQ:BCAX) showed a performance of 9.06% in past 30-days.

Wall Street analysts have assigned a consensus price target of 35 to the stock, which implies a rise of 62.86% to its current value. Analysts have been projecting 35 as a low price target for the stock while placing it at a high target of 35. It follows that stock’s current price would drop -169.23% in reaching the projected high whereas dropping to the targeted low would mean a loss of -169.23% for stock’s current value.

On the other hand, Price (T.Rowe) New Horizons Fund and AB Cap Fd.-AB Small Cap Growth Port are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 589.53 shares of worth $7.66 million or 1.08% of the total outstanding shares. The later fund manager was in possession of 400.96 shares on Dec 31, 2024 , making its stake of worth around $5.21 million in the company or a holder of 0.74% of company’s stock.